1. Home
  2. TYRA vs OFIX Comparison

TYRA vs OFIX Comparison

Compare TYRA & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • OFIX
  • Stock Information
  • Founded
  • TYRA 2018
  • OFIX 1987
  • Country
  • TYRA United States
  • OFIX United States
  • Employees
  • TYRA N/A
  • OFIX N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • OFIX Medical/Dental Instruments
  • Sector
  • TYRA Health Care
  • OFIX Health Care
  • Exchange
  • TYRA Nasdaq
  • OFIX Nasdaq
  • Market Cap
  • TYRA 819.3M
  • OFIX 722.6M
  • IPO Year
  • TYRA 2021
  • OFIX N/A
  • Fundamental
  • Price
  • TYRA $15.91
  • OFIX $18.36
  • Analyst Decision
  • TYRA Strong Buy
  • OFIX Strong Buy
  • Analyst Count
  • TYRA 6
  • OFIX 3
  • Target Price
  • TYRA $30.50
  • OFIX $23.00
  • AVG Volume (30 Days)
  • TYRA 261.4K
  • OFIX 213.3K
  • Earning Date
  • TYRA 03-18-2025
  • OFIX 03-04-2025
  • Dividend Yield
  • TYRA N/A
  • OFIX N/A
  • EPS Growth
  • TYRA N/A
  • OFIX N/A
  • EPS
  • TYRA N/A
  • OFIX N/A
  • Revenue
  • TYRA N/A
  • OFIX $784,249,000.00
  • Revenue This Year
  • TYRA N/A
  • OFIX $8.83
  • Revenue Next Year
  • TYRA N/A
  • OFIX $6.32
  • P/E Ratio
  • TYRA N/A
  • OFIX N/A
  • Revenue Growth
  • TYRA N/A
  • OFIX 17.32
  • 52 Week Low
  • TYRA $12.34
  • OFIX $12.08
  • 52 Week High
  • TYRA $29.60
  • OFIX $20.73
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 52.83
  • OFIX 61.35
  • Support Level
  • TYRA $15.75
  • OFIX $16.52
  • Resistance Level
  • TYRA $17.27
  • OFIX $17.75
  • Average True Range (ATR)
  • TYRA 0.91
  • OFIX 0.48
  • MACD
  • TYRA 0.20
  • OFIX 0.14
  • Stochastic Oscillator
  • TYRA 65.99
  • OFIX 94.85

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Share on Social Networks: